GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Asset Turnover

Sophiris Bio (Sophiris Bio) Asset Turnover : 0.00 (As of Sep. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Sophiris Bio's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. Sophiris Bio's Total Assets for the quarter that ended in Sep. 2019 was $6.77 Mil. Therefore, Sophiris Bio's Asset Turnover for the quarter that ended in Sep. 2019 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Sophiris Bio's annualized ROE % for the quarter that ended in Sep. 2019 was 149.35%. It is also linked to ROA % through Du Pont Formula. Sophiris Bio's annualized ROA % for the quarter that ended in Sep. 2019 was -56.66%.


Sophiris Bio Asset Turnover Historical Data

The historical data trend for Sophiris Bio's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Asset Turnover Chart

Sophiris Bio Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sophiris Bio Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sophiris Bio's Asset Turnover

For the Biotechnology subindustry, Sophiris Bio's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophiris Bio's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Asset Turnover falls into.



Sophiris Bio Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Sophiris Bio's Asset Turnover for the fiscal year that ended in Dec. 2018 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=0/( (26.877+13.199)/ 2 )
=0/20.038
=0.00

Sophiris Bio's Asset Turnover for the quarter that ended in Sep. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2019 )/( (Total Assets (Q: Jun. 2019 )+Total Assets (Q: Sep. 2019 ))/ count )
=0/( (6.441+7.099)/ 2 )
=0/6.77
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Sophiris Bio  (OTCPK:SPHS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Sophiris Bio's annulized ROE % for the quarter that ended in Sep. 2019 is

ROE %**(Q: Sep. 2019 )
=Net Income/Total Stockholders Equity
=-3.836/-2.5685
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.836 / 0)*(0 / 6.77)*(6.77/ -2.5685)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-2.6358
=ROA %*Equity Multiplier
=-56.66 %*-2.6358
=149.35 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Sophiris Bio's annulized ROA % for the quarter that ended in Sep. 2019 is

ROA %(Q: Sep. 2019 )
=Net Income/Total Assets
=-3.836/6.77
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-3.836 / 0)*(0 / 6.77)
=Net Margin %*Asset Turnover
= %*0
=-56.66 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Sophiris Bio Asset Turnover Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophiris Bio (Sophiris Bio) Business Description

Traded in Other Exchanges
N/A
Address
1258 Prospect Street, La Jolla, CA, USA, 92037
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.
Executives
Randall E Woods director, officer: President & Chief Exec Officer C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell director
Gerald T Proehl director
John Geltosky director 685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067